Drugs / ZSP1241
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03734926 | Nov 2018 → Oct 2021 | cholangiocarcinoma, colorectal cancer, esophageal cancer, gastric cancer +1 | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZSP1241 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03734926 ↗ |
| Route | Oral | “ZSP1241 tablets for oral administration.” NCT03734926 ↗ |